The Antimicrobial Removal Device (ARD), BACTEC 16B medium, and Thiol broth were evaluated for their effectiveness in reducing the activity of imipenem (IPM), cefoxitin, moxalactam, and ceftazidime in blood samples. In addition, the capability of the ARD and Thiol broth to bind norfloxacin and the ARD to bind oxolinic and nalidixic acids in urine samples was investigated. At the highest concentrations of the drugs tested (32 ,ug/ml for the four ,-lactams and 256 ,ug/ml for the three quinolinecarboxylic acids), there was at least a 95% reduction in the in vitro activity of each of the antibacterial agents for treated versus untreated samples. Of the compounds tested in the ARD system, the organic acids were more completely removed than were the P-lactams. The Thiol broth was more effective than the ARD and the BACTEC 16B medium in inactivating imipenem, but it had no effect on the antibacterial activity of norfloxacin.
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Proper management of bacteremia is highly dependent upon prompt isolation of the causative organism. Basically, this is also true of infections associated with other body fluids. The empiric initiation of antibiotic therapy before specimen collection is known to prevent or delay the recovery of the offending organism (3). For this reason, there are presently available at least three systems that are capable of inactivating or removing most of the antimicrobial agents currently used in septicemic patients. The Antimicrobial Removal Device (ARD; Marion Scientific, Kansas City, Mo.) and BACTEC 16B medium (Johnston Laboratories, Cockeysville, Md.) are two such systems that utilize resins to bind up the antibiotic (1, 2, 4, 6, 7). Thiol broth (Difco Laboratories, Detroit, Mich.) inactivates a variety of antimicrobial agents by a mechanism that still remains to be defined (5; the promotional literature of the manufacturer). The ARD requires processing of the blood sample before culturing in a regular blood culture medium. No such prior manipulation of the specimen is needed with either Thiol broth or BACTEC 16B medium; both of these are essentially blood culture media which have been supplemented with appropriate chemical inactivators or removers.
Both imipenem (IPM) and norfloxacin are remarkably potent broad spectrum antibacterial agents that will soon become available clinically for a wide range of therapeutic indications (IPM) or for prophylaxis and therapy of urinary tract infections (norfloxacin). The present study was undertaken to determine the effectiveness of Thiol broth, BAC-TEC 16B medium, and the ARD in neutralizing the antibacterial activities of IPM, norfloxacin, and related drugs contained in blood or urine samples.
MATERIALS Processing of blood samples. Aqueous stock -antibiotic solutions were diluted in human whole blood in volumes of 4 ml for testing with BACTEC 16B medium or 6 ml for testing with Thiol broth and ARD. The range of concentrations tested for each antibiotic included the clinically significant plasma levels. The ARD bottles were injected with 5 ml of the antibiotic-containing blood sample and allowed to rotate for 15 min at room temperature. The BACTEC 16B medium vials were injected with 3 ml of the blood sample and agitated at room temperature for 30 min. As for the Thiol broth, each bottle received 5 ml of the blood sample and was mixed briefly before being incubated at 37°C for 60 min. After these various treatments, 1-ml portions of treated and untreated samples were centrifuged, and supernatants were assayed in 20-,ll quantities for antibiotic contents by the microbiological disk diffusion method, with 1/4" (0.635 cm) blank paper disks (Schleicher & Schuell; no. 740E) and Bacillus subtilis ATCC 6633 for IPM, Staphylococcus aureus ATCC 29608 (MB 2786) for cefoxitin, and Klebsiella pneumoniae ATCC 10031 for moxalactam and ceftazidime. Antibiotic concentrations (in micrograms per milliliter) in pre-and posttreatment samples were determined by reference to standard curves.
Removal of antibiotics from urine. Norfloxacin, nalidixic, and oxolinic acids were dissolved in 0.1 N NaOH and diluted serially in 6-ml volumes of human urine to within levels achievable clinically. The urine used was tested for antimicrobial activity before the experiment. Samples (5 ml) of the drug-containing urine test solutions were treated in the ARD for 15 min or the Thiol broth for 60 min. The amount of antibiotic per milliliter of untreated and ARD-treated samples was determined as described previously, using K. pneumoniae ATCC 10031 as the assay organism. an initial blood concentration of ca. 32 sy.g/ml, the bioassays ed 10-fold when subsequently inoculated into regular blood of IPM show a reduction to less than 0.3 ,ug/ml (>99.2% culture media, thus reducing the potential need to reprocess reduction), 1.4 ,ug/ml (95.5% reduction), and 1.9 ,ug/ml thé sample to achieve a subinhibitory level of the drug. For (94.9% reduction) after proper treatment in the Thiol broth, economical considerations, one should be reminded that in ARD, and BACTEC 16B medium, respectively. In compari-addition to the added cost of the routine media, the ARD is son with the ARD and BACTEC 16B medium, the Thiol considerably more expensive than the Thiol broth and is broth was somewhat less effective in neutralizing the anti-theoretically more prone to bacterial contamination. bacterial activity of cefoxitin. Moxalactam was inactivated The ARD was evaluated for its ability to reduce to below or was bound equally well in all three systems, from an initial therapeutic levels the amount of norfloxacin, nalidixic, and concentration of ca. 32 jxgl/nl to 1.1, 1.9, and 1.4 ,ug/ml for oxolinic acids (Table 2 ) contained in urine samples. At the the ARD, BACTEC 16B medium, and Thiol broth, respec-highest urinary drug concentration tested (ca. 256 ,ug/ml), tively. BACTEC 16B medium was more effective than the the ARD was capable of binding up to 99.9% of norfloxacin Other two devices in inactivatinig ceftazidimé in blood speci-and oxolinic acid and at leàst 98.8% of nalidixic acid initially mens as shown by à reduction in the bioassays of this present in the specimen. These results also seem to suggest colnpound from ca. 32 to 0.05 ,ug/m1 for BACTEC 16B that the ARD was inore effective in removing the organic medium, 0.5 ptg/ml for thé ARD, and 0.7 ,ug/ml for Thiol acids from urine than the P-lactam antibiotics from blood. In broth. The efficacy of tlie resin-containing devices (ARD and addition to the ARD, the Thiol broth also was examined for BACTEC 168 medium) in removing P-lactam antibiotics its ability to neutralize the antibacterial activity of norfloxafrom blood samples was at least twofold greater for cefoxitin cin in urine. After the effect of a 1d-fold dilution of the and ceftazidime thari for IPM and moxalactam. The low-original urine sample itlto the Thiol broth was accounted for, 
